<p>史密斯与内甫公司 (LON:SN - 获取免费报告) 在周五创下了新的 52 周高点。该股最高交易价格为 GBX 1,250.50，最后交易价格为 GBX 1,248，成交量为 1,196,793 股。该股此前收盘价为 GBX 1,240.50。</p>
<p>获取 <strong>Smith &amp; Nephew</strong> 警报：</p>
<h2>分析师评级变动</h2>
<p>几家券商最近对 SN 进行了评论。加拿大皇家银行将史密斯与内甫的评级下调至 “行业表现”，并在 12 月 17 日的研究报告中将该股的目标价从 GBX 1,700 下调至 GBX 1,350。贝伦贝格银行在 1 月 23 日的研究报告中重申了 “持有” 评级，并将史密斯与内甫的目标价设定为 GBX 1,300。最后，潘穆尔·戈登在 12 月 9 日的报告中重申了 “持有” 评级，并将史密斯与内甫的目标价设定为 GBX 1,200。两位股票研究分析师对该股给予了买入评级，四位分析师对该公司的股票给予了持有评级。根据 MarketBeat.com 的数据，该股目前的共识评级为 “持有”，平均目标价为 GBX 1,381.33。</p>
<p><strong>阅读我们对史密斯与内甫的最新分析</strong></p>
<h2>史密斯与内甫的价格表现</h2>
<p>该公司的市值为 136.8 亿英镑，市盈率为 44.93，市盈增长比率为 0.46，贝塔值为 0.68。公司的债务与股本比率为 62.90，流动比率为 2.57，速动比率为 0.84。该公司的 50 日移动平均线为 GBX 1,272.11，200 日移动平均线为 GBX 1,298.93。</p>
<h2>关于史密斯与内甫</h2>
<p>(获取免费报告)</p>
<p>史密斯与内甫公司及其子公司在英国及国际上开发、制造、营销和销售医疗设备和服务。它通过三个部门运营：骨科、运动医学与耳鼻喉科，以及先进的伤口管理。该公司提供用于膝关节置换手术的膝关节植入产品；用于修复手术的髋关节植入物；包括用于稳定严重骨折和畸形矫正手术的内部和外部设备的创伤和四肢产品；以及其他重建产品。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票比史密斯与内甫更好</li>
<li>马丁·韦斯的个人警告（请阅读）</li>
<li>SpaceX IPO 确认：立即索取您的股份</li>
<li>伊朗并不是真正的战争</li>
<li>这枚硬币一切都在向好发展</li>
<li>今天只有 500 人……</li>
</ul>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在史密斯与内甫吗？</h2>
<p>在考虑史密斯与内甫之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而史密斯与内甫并不在名单上。</p>
<p>虽然史密斯与内甫目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>史密斯与内甫（Smith & Nephew，伦敦证券交易所代码：SN）达到了新的 52 周高点，价格为 1250.50 英镑，收盘价为 1248 英镑，交易量为 1,196,793 股。分析师们的意见不一，加拿大皇家银行将该股票评级下调至 “行业表现”，并将目标价下调至 1350 英镑。贝伦贝格银行和潘穆尔·戈登维持 “持有” 评级，目标价分别为 1300 英镑和 1200 英镑。该股票的市值为 136.8 亿英镑，市场共识评级为 “持有”，平均目标价为 1381.33 英镑</p>

<p>Smith &amp; Nephew plc (LON:SN - Get Free Report) hit a new 52-week high on Friday . The stock traded as high as GBX 1,250.50 and last traded at GBX 1,248, with a volume of 1196793 shares trading hands. The stock had previously closed at GBX 1,240.50.</p>
<div class="lb-trans"><p>史密斯与内甫公司 (LON:SN - 获取免费报告) 在周五创下了新的 52 周高点。该股最高交易价格为 GBX 1,250.50，最后交易价格为 GBX 1,248，成交量为 1,196,793 股。该股此前收盘价为 GBX 1,240.50。</p>
</div><p>Get <strong>Smith &amp; Nephew</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Smith &amp; Nephew</strong> 警报：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several brokerages have recently commented on SN. Royal Bank Of Canada downgraded Smith &amp; Nephew to a &#34;sector perform&#34; rating and lowered their price objective for the stock from GBX 1,700 to GBX 1,350 in a research note on Wednesday, December 17th. Berenberg Bank reaffirmed a &#34;hold&#34; rating and set a GBX 1,300 target price on shares of Smith &amp; Nephew in a research report on Friday, January 23rd. Finally, Panmure Gordon reiterated a &#34;hold&#34; rating and set a GBX 1,200 price target on shares of Smith &amp; Nephew in a report on Tuesday, December 9th. Two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of &#34;Hold&#34; and an average price target of GBX 1,381.33.</p>
<div class="lb-trans"><p>几家券商最近对 SN 进行了评论。加拿大皇家银行将史密斯与内甫的评级下调至 “行业表现”，并在 12 月 17 日的研究报告中将该股的目标价从 GBX 1,700 下调至 GBX 1,350。贝伦贝格银行在 1 月 23 日的研究报告中重申了 “持有” 评级，并将史密斯与内甫的目标价设定为 GBX 1,300。最后，潘穆尔·戈登在 12 月 9 日的报告中重申了 “持有” 评级，并将史密斯与内甫的目标价设定为 GBX 1,200。两位股票研究分析师对该股给予了买入评级，四位分析师对该公司的股票给予了持有评级。根据 MarketBeat.com 的数据，该股目前的共识评级为 “持有”，平均目标价为 GBX 1,381.33。</p>
</div><p><strong>Read Our Latest Analysis on Smith &amp; Nephew</strong></p>
<div class="lb-trans"><p><strong>阅读我们对史密斯与内甫的最新分析</strong></p>
</div><h2>Smith &amp; Nephew Price Performance</h2>
<div class="lb-trans"><h2>史密斯与内甫的价格表现</h2>
</div><p>The firm has a market cap of £13.68 billion, a PE ratio of 44.93, a P/E/G ratio of 0.46 and a beta of 0.68. The company has a debt-to-equity ratio of 62.90, a current ratio of 2.57 and a quick ratio of 0.84. The business's fifty day moving average is GBX 1,272.11 and its 200-day moving average is GBX 1,298.93.</p>
<div class="lb-trans"><p>该公司的市值为 136.8 亿英镑，市盈率为 44.93，市盈增长比率为 0.46，贝塔值为 0.68。公司的债务与股本比率为 62.90，流动比率为 2.57，速动比率为 0.84。该公司的 50 日移动平均线为 GBX 1,272.11，200 日移动平均线为 GBX 1,298.93。</p>
</div><h2>About Smith &amp; Nephew</h2>
<div class="lb-trans"><h2>关于史密斯与内甫</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Smith &amp; Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine &amp; ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.</p>
<div class="lb-trans"><p>史密斯与内甫公司及其子公司在英国及国际上开发、制造、营销和销售医疗设备和服务。它通过三个部门运营：骨科、运动医学与耳鼻喉科，以及先进的伤口管理。该公司提供用于膝关节置换手术的膝关节植入产品；用于修复手术的髋关节植入物；包括用于稳定严重骨折和畸形矫正手术的内部和外部设备的创伤和四肢产品；以及其他重建产品。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Smith &amp; Nephew</li>
<li>A personal warning from Martin Weiss (Please read)</li>
<li>SpaceX IPO Confirmed: Claim Your Stake Today</li>
<li>Iran isn't the real war</li>
<li>This coin has everything going for it</li>
<li>Only 500 people today…</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比史密斯与内甫更好</li>
<li>马丁·韦斯的个人警告（请阅读）</li>
<li>SpaceX IPO 确认：立即索取您的股份</li>
<li>伊朗并不是真正的战争</li>
<li>这枚硬币一切都在向好发展</li>
<li>今天只有 500 人……</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Smith &amp; Nephew Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在史密斯与内甫吗？</h2>
</div><p>Before you consider Smith &amp; Nephew, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑史密斯与内甫之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith &amp; Nephew wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而史密斯与内甫并不在名单上。</p>
</div><p>While Smith &amp; Nephew currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然史密斯与内甫目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Smith and Nephew (LON:SN) 达到新的一年高点 - 以下是原因